文献速递泌尿男性生殖肿瘤

低危前列腺癌患者接受大分割放疗与常规放疗后的生活质量:一项3期随机临床试验

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项3期随机临床试验纳入美国、加拿大和瑞士低危前列腺癌患者,随机接受常规放疗(73.8 Gy/41次/8.2周)或大分割放疗(70 Gy/28次/5.6周),962例患者同意参与生活质量分析。除12个月时大分割组肠道领域评分下降较常规组更大(平均评分-7.5 vs -3.7,P<.001)但未达临床显著性(效应量=0.29)外,各领域变化评分两组间无差异。作者认为大分割放疗在无病生存和生活质量方面不劣于常规放疗,是低危前列腺癌的实践标准。

要点

  • 大分割放疗(70 Gy/28次/5.6周)与常规放疗(73.8 Gy/41次/8.2周)在低危前列腺癌患者中各生活质量领域变化评分总体无差异。
  • 仅12个月时大分割组肠道领域评分下降大于常规组(平均-7.5 vs -3.7,P<.001),但未达临床显著性(效应量=0.29)。
  • 作者结论认为大分割放疗在无病生存及前列腺癌特异性和总体生活质量方面不劣于常规放疗。

核心结论

  • 在低危前列腺癌患者中,大分割放疗在无病生存以及前列腺癌特异性(如肠道、膀胱、性功能)和总体生活质量、焦虑和抑郁方面不劣于常规放疗。
  • 本研究提供证据确认大分割放疗是低危前列腺癌患者的实践标准。

研究设计与样本

  • 3期随机临床试验,患者来自美国、加拿大和瑞士的国家癌症研究所国家临床试验网络站点。
  • 低危前列腺癌患者随机接受常规放疗(73.8 Gy分41次,历时8.2周)或大分割放疗(70 Gy分28次,历时5.6周)。
  • 主要终点可分析患者1092例,其中962例(平均[SD]年龄66.6[7.4]岁)同意参与生活质量分析。
  • 生活质量采用扩展前列腺指数综合问卷(肠道、泌尿、性、激素领域)、25项霍普金斯症状清单(焦虑和抑郁)和EuroQol-5维度问卷(总体生活质量)评估,基线及6、12、24、60个月收集数据。
  • 变化评分采用Wilcoxon符号秩检验比较,多重比较校正显著性水平为.0125,总体双侧1型错误为.05;扩展前列腺指数综合问卷变化评分的临床显著性由效应量0.5确定。

主要发现

  • 两组基线特征及任何生活质量基线领域评分均无统计学显著差异。
  • 除12个月时大分割组肠道领域评分下降大于常规组(平均评分-7.5 vs -3.7,P<.001)但未达临床显著性(效应量=0.29)外,扩展前列腺指数综合问卷各领域变化评分两组间无差异。
  • 霍普金斯症状清单和EuroQol-5维度问卷在任何时间点两组间均无差异。

临床怎么用

  • 作者结论认为大分割放疗是低危前列腺癌患者的实践标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypofractionated radiotherapy (HRT) would be more convenient for men with low-risk prostate cancer and cost less than conventional radiotherapy (CRT) as long as HRT is noninferior to CRT in terms of survival and quality of life (QOL) is not found to be worse. OBJECTIVE: To assess differences in QOL between men with low-risk prostate cancer who are treated with HRT vs CRT. DESIGN, SETTING, AND PARTICIPANTS: In this phase 3 randomized clinical trial, men with low-risk prostate cancer were enrolled from sites within the National Cancer Institute's National Clinical Trials Network in the United States, Canada, and Switzerland. INTERVENTIONS: Random assignment to CRT (73.8 Gy in 41 fractions over 8.2 weeks) or to HRT (70 Gy in 28 fractions over 5.6 weeks). MAIN OUTCOMES AND MEASURES: Quality of life was assessed using the Expanded Prostate Index Composite questionnaire measuring bowel, urinary, sexual, and hormonal domains; the 25-item Hopkins Symptom Checklist measuring anxiety and depression; and the EuroQol-5 Dimension questionnaire measuring global QOL. All data were collected at baseline and 6, 12, 24, and 60 months. Change scores were compared between treatment arms using the Wilcoxon signed rank test. A significance level of .0125 to adjust for multiple comparisons was used for an overall 2-sided type 1 error of .05. Clinical significance was determined for the Expanded Prostate Index Composite change scores by an effect size of 0.5. RESULTS: Of 1092 patients analyzable for the primary end point, 962 (mean [SD] age, 66.6 [7.4] years) consented to the QOL component. No statistically significant differences with regard to baseline characteristics nor any of the QOL baseline domains were measured between arms. There were no differences in change score between arms with respect to any of the Expanded Prostate Index Composite questionnaire domain scores except at 12 months when the HRT arm had a larger decline than the CRT arm in the bowel domain (mean score, -7.5 vs -3.7, respectively; P<.001), but it did not reach clinical significance (effect size = 0.29). There were no differences between arms at any time point for the Hopkins Symptom Checklist nor EuroQol-5 Dimension questionnaire. CONCLUSIONS AND RELEVANCE: Treatment with HRT is noninferior to CRT in men with low-risk prostate cancer in terms of disease-free survival and, as shown in the present study, in prostate cancer-specific (eg, bowel, bladder, sexual) and general QOL, as well as in anxiety and depression. This study provides evidence to affirm that HRT is a practice standard for men with low-risk prostate cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00331773.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bruner DW, Pugh SL, Lee WR, et al. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30763425. doi:10.1001/jamaoncol.2018.6752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。